AI assistant
FDC Ltd. Earnings Release 2021
60812_rns_2021-05-27_ec7894d5-74f4-44ca-b6d4-23fe824c3269.pdf
Earnings Release
Open in viewerOpens in your device viewer
MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS
May 27,2021
BSELimited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001
BSEScript Code: 531599
National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051
NSE Symbol: FDC
Sub: Press Release
Dear Sir/Ma'am,
Please find attached herewith the Press Release issued in relation to the Audited Standalone and Consolidated Financial Results of the Company for the quarter & year ended March 31, 2021.
Kindly take the same on record.
Thanking you,
Yours truly
ForF,DCLim
.~ i Katre Company Secretary F-8948
CORPORATE OFFICE
REGISTERED OFFICE
: 142-48. S. V. Road, Jogeshwari (W), Mumbai - 400102. INDIA Tel.: +91-22-6291 7900/950/2678 0652 / 2653 / 2656 • Fax: +91-22-2677 3462 E-mail: [email protected] • Website: www.fdcmdla.corn
: 8-8, M.I.D.C. Industrial Area. Waluj - 431 136, Dist. Aurangabad. INDIA Tel.: 0240-2554407/2554299/2554967 • Fax: 0240-2554299 E-mail: [email protected] • CIN : L24239MH 1940PLC003176
FDC Limited reports Q4FY21 and FY21 results
Mumbai, 27th May, 2021: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the fourth quarter ending 31st March, 2021.
Consolidated Q4FY21 and FY21 FDC reported:
| Rs. in lakhs | Q4' 20-21 | Q4' 19-20 | YOY Growth % |
|---|---|---|---|
| Operating Revenues | 31,339.90 | 33,333.16 | -5.98% |
| EBITDA | 6,657.99 | 6,704.92 | -0.70% |
| EBITDA % | 20.28% | 18.07% | 12.23% |
| PBT | 5,385.05 | 5,673.40 | -5.08% |
| PAT | 4,675.93 | 5,548.35 | -15.72% |
| EPS | 2.77 | 3.22 | -13.98% |
| Rs. in lakhs | FY21 | FY21 | YOY Growth % |
|---|---|---|---|
| Operating Revenues | 133,320.34 | 134,419.12 | -0.82% |
| EBITDA | 43,108.25 | 36,184.12 | 19.14% |
| EBITDA % | 30.14% | 25.61% | 17.69% |
| PBT | 38,770.69 | 32,096.70 | 20.79% |
| PAT | 30,119.93 | 23,987.84 | 25.56% |
| EPS | 17.72 | 13.94 | 27.12% |
India Market:
Highlights:
- Q4 FY21 revenue at Rs. 235.15 Crore, down by 8.23 % YOY
- FY21 revenue at Rs. 992.59 Crore, down by 6.69 % YOY
Overall sales in the Indian market accounted for 75.54 % of total consolidated sales for the quarter. Anti-infective therapy market remained in lower demand in Q4FY21 and throughout FY21, and had a negative impact on FDC's sales in India.
Export Formulations Market:
Highlights:
- Q4 FY21 revenue at Rs. 57.17 Crore, down 7.50 % YOY
- FY21 revenue at Rs. 269.81 Crore, up by 20.83 % YOY
Registered Office: Waluj, Aurangabad, Maharashtra – 431 136. India
The main contributor was the USA market, accounting for 65.58 % of total Export Formulations Sales. Also, we have successfully registered 2 products in Uzbekistan and added this new territory in our Export formulation business.
Export API Market:
Highlights:
- Q4FY21 revenue at Rs. 18.96 Crore, up by 43.53 % YOY
- FY21 revenue at Rs. 60.75 Crore, up by 25.09 % YOY
ABOUT FDC LTD
Established in 1940, with the dream of building a world class company and vision to make the nation self-reliant in healthcare, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE, to cite a few. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS) and Ophthalmics. FDC has also set-up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 250 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life to billions globally.
Disclaimer
Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forwardlooking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.
